Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Spremljeno u:
Bibliografski detalji
Izdano u:J Gastrointest Oncol
Glavni autori: Schlintl, Verena, Huemer, Florian, Greil, Richard, Weiss, Lukas
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2021
Teme:
Letter to the Editor
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107630/
https://ncbi.nlm.nih.gov/pubmed/34012679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo-20-230
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items